Healthcare Services

Global Hematologic Malignancies Detection Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Hematologic Malignancies Detection Market Projected To Become By 2030 Based On Its 2026 Valuation?

Recent years have seen a quick rise in the size of the hematologic malignancies detection market. Projections indicate it will expand from $3.1 billion in 2025 to reach $3.57 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 15.5%. Historically, this expansion has been driven by several factors, including the rising prevalence of blood cancers, the uptake of pcr and immunochemistry techniques, a broader clinical laboratory infrastructure, heightened awareness regarding early cancer detection, and the presence of advanced diagnostic kits.

The market size for hematologic malignancies detection is projected to experience rapid expansion over the next few years. It is forecast to grow to $6.28 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.1%. This anticipated growth during the forecast period is primarily driven by the increasing integration of liquid biopsy diagnostics, rising investments within precision oncology, the expansion of genomic testing programs, the growing utilization of AI-based diagnostic platforms, and an enhanced focus on the early and accurate identification of cancer. Significant trends expected in this period encompass a greater adoption of molecular diagnostic techniques, the increasing application of next-generation sequencing in oncology, the expanding integration of AI in diagnostic interpretation, the broadening of early cancer screening initiatives, and a heightened emphasis on personalized oncology diagnostics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19504&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Hematologic Malignancies Detection Market?

The growing occurrence of blood cancer is anticipated to stimulate the expansion of the hematologic malignancy detection market in the future. This type of cancer encompasses various malignancies that impact the blood, bone marrow, or lymphatic system, thereby hindering the normal production and operation of blood cells. The rising incidence of blood cancer can be attributed to an aging populace and advancements in diagnostic methods, which facilitate earlier and more precise identification. Detecting hematologic malignancies is crucial for managing blood cancer, as it permits prompt and accurate diagnosis, paving the way for tailored and successful therapeutic approaches. For example, in March 2024, a Cancer Facts & Figures 2023 report, issued by the Leukemia & Lymphoma Society, a professional organization company based in the US, indicated that around 437,337 individuals are either living with or are in remission from leukemia within the US. Moreover, approximately 59,610 new instances are projected to be diagnosed during 2024. Consequently, the escalating occurrence of blood cancer is stimulating the expansion of the hematologic malignancy detection market.

What Segment Groups Are Identified Within The Hematologic Malignancies Detection Market?

The hematologic malignancies detection market covered in this report is segmented –

1) By Type: Polymerase Chain Reaction, Immunochemistry, Next Generation Sequencing, Fluorescence In Situ Hybridization

2) By Application: Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Myeloproliferative Neoplasms, Lymphoma, Other Applications

3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Polymerase Chain Reaction (PCR): Real-Time PCR (qPCR), Digital PCR, Reverse Transcription PCR (RT-PCR), Nested PCR, Multiplex PCR, PCR-Based Detection Kits

2) By Immunochemistry: Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry (IHC), Flow Cytometry, Immunofluorescence, Immunohistochemical Staining Kits

3) By Next Generation Sequencing (NGS): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq), Liquid Biopsy NGS, Next-Generation Sequencing Kits For Hematologic Malignancies

4) By Fluorescence In Situ Hybridization (FISH): Chromosome-Specific FISH Probes, DNA FISH, RNA FISH, Multicolor FISH, FISH-Based Detection Kits For Leukemia And Lymphoma

What Trends Are Affecting The Expansion Of The Hematologic Malignancies Detection Market?

Leading companies within the hematologic malignancy detection market are concentrating on developing innovative solutions, including blood cancer diagnostic tests, to boost diagnostic accuracy and improve patient outcomes. Blood cancer diagnostic tests play a critical role in identifying and confirming hematologic malignancies, such as leukemia, lymphoma, and multiple myeloma. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based research and treatment institution, launched PanHeme, an advanced blood cancer diagnostic test that employs next-generation gene sequencing technology for detecting hematologic malignancies. By utilizing next-generation sequencing technology, PanHeme accurately pinpoints genetic mutations in blood cancers like leukemia, lymphoma, and multiple myeloma within 72 hours, a speed considerably quicker than traditional approaches. This swift result delivery allows for personalized treatment plans, as healthcare providers can implement targeted FDA-approved therapies based on specific mutations.

Which Companies Hold Significant Positions In The Hematologic Malignancies Detection Market?

Major companies operating in the hematologic malignancies detection market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Roche Diagnostics International Ltd., Illumina Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Becton Dickinson and Company, Beckman Coulter Inc., Sysmex Corporation, Adaptive Biotechnologies Corporation, NeoGenomics Laboratories Inc., Invivoscribe Technologies Inc., ArcherDx Inc., Invitae Corporation, Natera Inc., Genetron Health, SOPHiA GENETICS, Guardant Health Inc., Genetica Diagnostics

Read the full hematologic malignancies detection market report here:

https://www.thebusinessresearchcompany.com/report/hematologic-malignancies-detection-global-market-report

Which Regions Are Projected To Dominate The Hematologic Malignancies Detection Market In The Coming Years?

North America was the largest region in the hematologic malignancies’ detection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies detection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hematologic Malignancies Detection Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19504&type=smp

Browse Through More Reports Similar to the Global Hematologic Malignancies Detection Market 2026, By The Business Research Company

Medical Radiation Detection Monitoring And Safety Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-radiation-detection-monitoring-and-safety-global-market-report

Defect Detection Global Market Report

https://www.thebusinessresearchcompany.com/report/defect-detection-global-market-report

Healthcare Fraud Detection Global Market Report

https://www.thebusinessresearchcompany.com/report/healthcare-fraud-detection-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795